INDV Indivior Pharmaceuticals, Inc.

Nasdaq Pharmaceutical Preparations DE CIK: 0001625297
AI RATING
SELL
88% Confidence

Investment Thesis

Despite strong gross margins (87.4%) and modest revenue growth (4.3%), Indivior faces critical solvency issues: negative stockholders' equity of -$144M, negative operating cash flow of -$9M, and deteriorating liquidity ratios. The dramatic net income recovery (+2900% YoY) masks underlying cash generation weakness and suggests reliance on non-cash accounting adjustments rather than sustainable operational improvement. Liquidity stress indicators and high debt burden ($486M) create significant refinancing risk.

Strengths

  • + Exceptional gross margin of 87.4% indicates strong product pricing power
  • + Operating margin of 28.1% net margin demonstrates efficient cost structure
  • + Positive interest coverage ratio of 3.6x provides near-term debt servicing capacity
  • + Holding $175M in cash equivalents provides liquidity buffer

Risks

  • ! Negative stockholders' equity of -$144M indicates balance sheet is technically insolvent
  • ! Negative operating cash flow (-$9M) and free cash flow (-$29M) despite GAAP profitability signals unsustainable business model
  • ! Current ratio of 0.86x and quick ratio of 0.66x indicate acute liquidity stress and potential covenant violations
  • ! Heavy debt load ($486M) combined with negative equity creates refinancing vulnerability
  • ! Large YoY profit swing suggests prior period losses eroding shareholder value; recovery may not be sustainable

Key Metrics to Watch

Financial Metrics

Revenue
317.0M
Net Income
89.0M
EPS (Diluted)
$0.69
Free Cash Flow
-29.0M
Total Assets
1.2B
Cash
175.0M

Profitability Ratios

Gross Margin 87.4%
Operating Margin 43.2%
Net Margin 28.1%
ROE N/A
ROA 7.4%
FCF Margin -9.1%

Balance Sheet & Liquidity

Current Ratio
0.86x
Quick Ratio
0.66x
Debt/Equity
N/A
Debt/Assets
112.0%
Interest Coverage
3.61x
Long-term Debt
486.0M
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings. It does not include stock price data and should not be considered financial advice. All fundamental data is sourced from SEC public domain filings. Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR | Analysis Date: 2026-05-06T17:56:18.610110 | Data as of: 2026-03-31 | Powered by Claude AI